This report gives the findings after two years of a study of long-term oral cytotoxic chemotherapy with busulphan or cyclophoshamide in carcinoma of the bronchus compared with two placebos, identical in appearance to the drug-containing tablets. A total of 753 patients who had had a total resection of the tumour, who had no detectable extrathoracic metastasis, and who were able to attend chest clinics monthly were admitted to the study from January 1965 to January 1968. Twenty-seven patients were excluded from all the analyses.
Introduction
Many deaths after potentially curative resection for carcinoma of the bronchus are due to distant metastases. These must cither have been present at the time of operation or have arisen from carcinoma cells circulating in the blood or from inapparent carcinoma tissue left in the thorax. It is possible that cytotoxic chemotherapy begun shortly after operation could keep metastases in check and prolong survival time.
Nitrogen mustard given in high dosage at the time of surgery, however, increased postoperative mortality in the first 30 days (Veterans Administration Adjuvant Cancer Chemotherapy Cooperative Group, 1961; Higgins et al., 1962) , while in lower dosage, though not increasing early postoperative mortality, it did not improve long-term survival . Nevertheless, as some investigators had reported favourably on long-term adjuvant chemotherapy with cyclophosphamide (Denk and Karrer, 1961; Poulsen, 1962 Poulsen, , 1963 it was decided in 1964 to study long-term cytotoxic chemotherapy with cyclophosphamide, chosen in view of the above favourable reports, and with busulphan, chosen because of its activity in inoperable bronchial carcinoma (Sullivan, 1958) and its relative freedom from side effects (Galton, 1953) .
This report gives the results up to two years; those up to five years will be reported later. Great Britain. These were centres in which the chest physicians in the area and the thoracic surgeon to whom they normally referred patients agreed to co-operate and where patients could be transferred from the care of the surgeon after discharge from hospital to that of the chest physician for the study follow-up.
PATIENTS ELIGIBLE FOR THE STUDY
Men of any age and women aged 45 or over were eligible for the study provided that: (a) the surgeon had just completed a total resection of the tumour, all visible intrathoracic growth having been removed; (b) there was a firm diagnosis of bronchial carcinoma (a few patients in whom the diagnosis was not confirmed histologically after operation were subsequently excluded); (c) there were no detectable extrathoracic mctastases; (d) the patient had not had radiotherapy or treatment with a cytotoxic drug before operation; (e) it was not planned to give a postoperative course of radiotherapy; (f) the chest physician had indicated that it would be possible for the patient to attend the chest clinic monthly for the control of chemotherapy; and (g) there were no known contraindications to the use of either cytotoxic drug under study. busulphan, and the other was bitter, containing 1 mg of quinine, similar in taste to cyclophosphamide.
CHEMOTHERAPY
All the tablets were identical in appearance, being specially made for the study. Each consisted of a core containing the active drug (or placebo) in its commercial formulation inside a compressed lactose coat. The tablets were supplied to the centres already labelled with a serial number for each patient in quantities sufficient for a six-month supply in the "early intake" and 12 months in the "late intake" (see below). ALLOCATION 
PRETREATMIENT OBSERVATIONS AND INVESTIGATIONS
Reports were completed by the surgeon on the patient's mode of presentation, the date of the first symptom, the preoperative general condition, weight, degree of dyspnoea, blood picture (including haemoglobin level, total and differential white cell count, and platelet count), and the operative findings. A preoperative chest radiograph was also sent to the unit.
A report was completed by the pathologist on the histological examination of the operation specimen, and slides of the primary tumour, of any involved intrathoracic lymph nodes, and of any preoperative bronchial biopsy specimen were sent to the reference pathologist.
FOLLOW-UP ASSESSMENTS
From the date of operationi mniulitlhly follow-up) rcports wcre sent by the physician (or the surgeon if the patient was still in hospital) on the patient's general condition, weight, degree of physical activity, degree of dyspnoea, results of examination for metastases, the haemoglobin estimation, total white cell and platelet counts, and details of the chemotherapy received in the previous month and prescribed for the next month.
Wherever possible a home visit was made during each month by a health visitor in order to assess the regularity of self-adniinistration of the drug by a count of the patient's stock of tablets.
REPORTS ON DEATH OF PATIENTS
When a patient died a report was obtained on the terminal illness, together with the findings of the final medical examination before death. If necropsy was performed a report of the findings was also obtained. Twenty-seven (8 B, 7 C, 12 P) patients have been excluded from all analyses-13 (4 B, 2 C, 7 P) had no evidence of carcinoma on histological examination of the resected specimen, 6 (2 B, 2 C, 2 P) died before chemotherapy could be started, 2 (1 B, 1 P) had an incomplete resection of the tumour, 2 (1 C, 1 P) had postoperative radiotherapy, for 2 (1 B, 1 C) supervision was not possible at a chest clinic, 1 (P) refused chemotherapy, and 1 (C) was a woman aged less than 45 years. After these exclusions 726 (243 B, 234 C, 249 P) patients remain in the analysis, 217 (76 B, 68 C, 73 P) in the early intake and 509 (167 B, 166 C, 176 P) in the late intake.
CONDITION ON ADMISSION TO THE STUDY
In both intakes the condition on admission and the clinical course of the patients who received the placebo resembling busulphan in taste and those who received the placebo resembling cyclophosphamide were very similar in all respects (data not tabulated here). Throughout the report, therefore, the two groups are amalgamated to form the single placebo (P) series.
The distributions were also similar for the three series for both intake periods. The condition on admission to the study for the patients in the three series is therefore set out in Table I for the early and late intakes combined. Nearly all the patients were male: 820/% of the B, 74% of the C, and 71% of the P group were aged 55 or more (P = 0O02, 2 D.F.); about half had a pneumonectomy; just over half had squamous tumours; and just under half had one or more nodes involved on histological examination of the resected specimen. Bronchopleural fistulae or empyemata occurred in 5 (7%) of the B, 9 (13%) of the C, and 3 (4o%) of the P patients in the early intake and in 10 (6 y) of the B, 9 (5%) of the C, and 4 (2 ,) of the P patients in the late intake (none of the differences were statistically significant). (Table II and Fig. I ). At 24 months 46% of the B, 44% of the C, and 49% of the P patients were alive in the early intake as were 49%, 50%, and 50% respectively in the late intake. There were no statistically significant differences between the series in either intake at any month.
SURVIVAL AT 24 MONTHS RELATED TO PRETREATMENT CONDITION
As detailed analyses showed no differences between the early and late intake in survival at 24 months related to the pretreatment condition, the patients in the two intakes have been amalgamated in Table III proportions were 62%/6, 56%, and 51%, and 51%, 57%, and 50%X, respectively. The proportions are also similar if only definite metastases are considered. Thus at six months they were 8%, 7%, and 5% respectively in the early intake and 8%'., 4%, and 7% in the late intake, at 12 months 16%, 15%, and 18% and 19%, 13%, and 20% respectively, at 24 months 29%, 24%, and 25°' and 24%, 21%, and 28% respectively.
CONDITION OF THE SURVIVORS AT 24 MONTHS
The general condition was reported as good for the majority of the patients alive at 24 months (Table IV) . Most were at work or on full activity but not at work (many were beyond retiring age), and many were able at least to walk any distance at normal pace on the flat without dyspnoea. Metastases were infrequent, being reported as definitely present in only 6% of the B, 6% of the C, and 8% of the P patients.
(3) Chemotherapy Received During the Two-year Period
START OF CHEMOTHERAPY
In all series the administration of the study tablets started shortly after operation. The intervals were, on average, 4-0 days for the B. 4-1 days for the C, and 4-0 days for the P patients. Further, nearly all the patients received eight tablets daily for 10 days as prescribed-namely, 92% of the 243 B, 94% of the 234 C, and 94% of the 249 P patients.
MAINTENANCE CHEMOTHERAPY
There were considerable differences between the series in the extent to which tablets were interrupted because of possible or definite toxicity. In each of the first three months few patients did not receive any tablets throughout the month (Table V) . In the early intake in the sixth month, however, 33% of the B, 21% of the C, and 5% of the P patients did not receive any tablets. Thereafter the proportions increased rarkedly in the busulphan series, becoming 89%, 19%', and 8% respectively, in the 24th month. In the late intake 16%' of the B, 12% of the C, and 5`' of the P patients did not receive any tablets in the sixth month. Thereafter the proportion increased substantially in the busulphan series, becoming 70%, 24%, and 10°o respectively in the 24th month. The proportion of patients receiving full dosage during the month in question is set out for the early and late intakes in Fig. 2. (4) Incidence of Toxicity DEATHS ATTRIBUTABLE TO CHEMOTHERAPY There were four busulphan (early intake) patients in whom there was evidence that the chemotherapy materially contributed to death. In two the death was certified as due to aplastic anaemia and in two to carcinoma of the bronchus. No patient died of toxicity in the other two series in the early intake or in any senes in the late intake.
Case 1.-A man of 71, after eight months on six tablets daily, had a haemoglobin level of 7.0 g/100 ml, a white cell count of 1,100/mm3, and no platelets. He had repeated transfusions but deteriorated and died after three weeks from aplastic anaemia. At necropsy the marrow of the humerus was greatly reduced. No metastases were found.
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Case 2.-A man of 58 received six tablets daily for three and a half months and then three tablets daily. At six months the platelet count had fallen to 73,000/mm3 but the tablets were not stopped as indicated in the protocol. At seven months the platelet count was 120,000 but at eight months it had fallen to 2,500, the haemoglobin level being 115/100 ml and the white cell count 4,500/mmnn. The tablets were then stopped, but in spite of the administration of corticosteroids and antibiotics the patient deteriorated and died of staphylococcal septicaemia in the 11th month. Necropsy showed no residual carcinoma or metastases. Case 3-A man of 57 received six tablets daily for three months and then three daily for one month, when they were stopped on account of a fall in the haemoglobin to 7.4 g/100 ml and in the platelet count to 30,000/mm.3 The haemoglobin continued to fall, reaching 4.7 g at six months, when the patient was transfused, and subsequently the platelets were reported to be less than 10,000. He died in the 10th month. Necropsy showed considerable hypoplasia of the bone marrow. There were metastases in the mediastinal nodes.
Case 4.-A man of 65 received six tablets daily for one month and then three tablets daily until five months, when the platelet count fell to 85,000/mm.3 After an interruption of one month the count rose to 200,000 and two tablets daily were resumed. At 11 months the platelet count had fallen to 60,000 and the tablets were interrupted for two months. At 13 months the count was 125,000 and two tablets daily were resumed, but reduced to one daily at 14 months because of a fall in platelets to 100,000 and finally stopped at 15 months because of a fall to 45,000. At this time spinal metastases were suspected. He died in the 18th month, necropsy showing subdural haemorrhage but no intracranial metastases; many mediastinal nodes were involved by tumour.
INCIDENCE OF TOXICITY AND CLINICAL ACTION TAKEN
The placebo series is considered first in order to provide a baseline for the other two series. Toxicity was reported in 49% of the 73 P patients in the early intake (Table VI) . Clinical toxicity occurred in 33%, the majority of symptoms being "gastric"~(defined as nausea, abdominal discomfort, vomiting, and jaundice); haematological toxicity occurred in 18%, 14% having thrombocytopenia (defined as a fall in the platelets below 100,000/MM3. In the late intake 36% of the 176 P patients had toxicity. Clinical toxicity occurred in 15% and haematological in 20%.
In both early and late intakes clinical toxicity was reported most frequently in the first three months and haematological toxicity most frequently in the first six months.
Busuiphan Series
Of the 76 B patients in the early intake 89% had toxicity (Table VI) . Clinical toxicity occurred in 30% (some also had haematological toxicity at the time), virtually all the symptoms being "gastric." Haematological toxicity occurred in 83 %. Anaemia (defined as a fall of haemoglobin below 9 g/ 100 ml) occurred in 24%, transfusions being given to 12 (16%) of the patients. Leucopenia (defined as a fall in total white cell count below 3,000/mm3) occurred in 29%. Thrombocytopenia occurred in 80% and tended to persist in spite of stopping the tablets. Thus 12 (36%) of 33 patients alive at 24 months who had had thrombocytopenia still had a platelet count below 100,000 at 24 months. Pancytopenia occurred in 11 (14%) patients. Of these, six died before 24 months, little or no improvement in the blood picture having occurred before death -three of carcinomatosis, one of bronchopneumonia, and two (cases 1 and 3 above) of aplastic anaemia. None of the five surviving patients who had had pancytopenia had a platelet count above 100,000 at 24 months. BRITISH MEDICAL JOURNAL 22 MAY 1971 In the late intake toxicity occurred in 80% of the 167 B patients. Clinical toxicity occurred in 17%, the majority of symptoms being "gastric." Haematological toxicity occurred in 690; 10%/ had anaemia, transfusions being required in 7 (4%) patients, 14%/ had leucopenia, 66% thrombocytopenia, and 4%/ pancytopenia. As The main early finding of this study was the unexpectedly high incidence of hazardous toxicity with busulphan. The dosage of busulphan had been selected on the basis of previous experience in chronic myeloid leukaemia, but even in this disease aplastic anaemia is a distinct risk (Weatherall et al., 1969) . There was also a high incidence of side effects in the cyclophosphamide series but these were less serious. As a result the maintenance dosage of both cytotoxic drugs was halved after the study had been in progress for 11 months. The data on toxicity illustrate the importance of keeping a close watch on the progress of individual patients as well as undertaking interim analyses in the course of a study. The lowering of the maintenance dosage resulted in two dosage groups, the high maintenance dosage "early intake" and the low maintenance dosage "late intake," which meant that the intake period had to be prolonged to admit a total of about 750 patients rather than 600 as originally planned. It also added to the complexity of the analysis and of the present report.
The therapeutic results at two years are disappointing, for there is no evidence that either of the two cytotoxic drugs in the dosage used improved survival, either in the early intake with the higher maintenance dosage or in the late intake with the lower maintenance dosage. Further, none of the subsidiary groups analysed, particularly with regard to age, sex, and histological type of tumour, showed meaningful differences between the series in survival. Thus, as used in this study, neither cytotoxic drug was beneficial.
Most of the patients in this study who died had evidence of recurrence of the disease, and there was no difference between the series in either the time of onset of metastases or the cause of death. Further, though postoperative infective complications were more frequent in the two cytotoxic drug series than the placebo series there was no evidence of an increased incidence of death due to infection in either the busulphan or the cyclophosphamide series.
Though in the past few years other investigators have reported benefit from the use of cyclophosphamide as an adjuvant to surgery for carcinoma of the bronchus (Karrer, 1965 (Karrer, , 1967 Kutschera and Schnetzer, 1965; Poulsen, 1965; Pfeiffer et al., 1966) only one studied concurrent randomly allocated controls. One study of 30 patients (Horwitz et al., 1965) has also reported benefit from the use of chlorambucil as suppres-427 sive chemotherapy in carcinoma of the bronchus after irradiation. Karrer (1970) reported observations suggesting that patients receiving daily cyclophosphamide do less well than patients receiving cyclophosphamide intermittently. Karrer (1967) reported that patients with carcinoma of the bronchus who developed leucopenia after treatment with cyclophosphamide had a better prognosis than those who did not, though he did not present evidence that the two groups were similar in other respects. Bross et al. (1966a Bross et al. ( , 1966b ) queried whether it is necessary to give toxic doses of cytotoxic drugs in order to ensure that a therapeutic effect is achieved. In the present study there was no direct evidence that patients who developed toxicity to either of the cytotoxic drugs did better than those who did not, though this will be examined in more detail, taking into consideration factors of possible prognostic importance. The detailed analysis will be reported, together with multiple regression analysis of these factors, when the five-year survival data are available.
The period of observation reported here is two years. All the surviving patients are, however, being followed up to five years, and none have so far been lost to observation. A final evaluation of the adjuvant chemotherapy as studied in this investigation will be made when the full five-year results are available.
The following surgeons, physicians, and pathologists co-operated in the study.
